Lessons learned from statin trials | Zendy

Auer J. | Zendy; Bebrent R. | Zendy; Eber B. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lessons learned from statin trials

Author(s) -

Auer J.,

Bebrent R.,

Eber B.

Publication year - 2001

Publication title -

clinical cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.263

H-Index - 72

eISSN - 1932-8737

pISSN - 0160-9289

DOI - 10.1002/clc.4960240404

Subject(s) - medicine , coronary artery disease , statin , clinical trial , intensive care medicine , atherosclerotic cardiovascular disease , hydroxymethylglutaryl coa reductase inhibitors , disease , cardiology

This article aims to review lessons learned about lipid lowering and statins in the past decade and to consider what developments the future may hold. Results from a series of landmark clinical trials confirm that statins significantly reduce cardiovascular morbidity and mortality in patients with and without previous coronary artery disease. The potential of this drug class has yet to be fully explored. Studies currently under way will answer many of the outstanding questions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research